Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials |
Wang, Wei-Lan
(Department of Pharmaceutical Care, Chinese PLA General Hospital)
Tang, Zhi-Hui (Department of Pharmaceutical Care, Chinese PLA General Hospital) Xie, Ting-Ting (Department of Pharmaceutical Care, Chinese PLA General Hospital) Xiao, Bing-Kun (Department of pharmacochemistry, Institute of Radiation Medicine) Zhang, Xin-Yu (Department of Pharmacy, Bengbu Medical University) Guo, Dai-Hong (Department of Pharmaceutical Care, Chinese PLA General Hospital) Wang, Dong-Xiao (Department of Pharmaceutical Care, Chinese PLA General Hospital) Pei, Fei (Department of Pharmaceutical Care, Chinese PLA General Hospital) Si, Hai-Yan (Department of Oncology, Chinese PLA General Hospital) Zhu, Man (Department of Pharmaceutical Care, Chinese PLA General Hospital) |
1 | Berk V, Kaplan MA, Tonyali O, et al (2013). Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 14, 7367-9. 과학기술학회마을 DOI ScienceOn |
2 | Blau HM, Banfi A (2001). The well-tempered vessel. Nat Med, 7, 532-4. DOI |
3 | Blumenschein GR Jr, Saintigny P, Liu S, et al (2013). Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res, 19, 6967-75 DOI |
4 | Carmeliet P, Jain RK (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-57 DOI ScienceOn |
5 | de Marinis F, Grossi F (2008). Clinical evidence for second- and third-line treatment options in advanced non-small cell lung cancer. Oncologist, 13 Suppl 1, 14-20 |
6 | Escudier B, Eisen T, Stadler WM, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 56, 125-34 |
7 | Ferlay J, Shin HR, Bray F, et al (2010). GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No.10 [Internet]. Lyon, France: International Agency for Research on Cancer. Available: http://www. globocan. iarc.fr. Accessed 16 January 2012. |
8 | Ferrara N, Kerbel RS (2005). Angiogenesis as a therapeutic target. Nature, 438, 967-74 DOI ScienceOn |
9 | Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov, 6, 273-86. DOI ScienceOn |
10 | Spigel DR, Burris HA 3rd, Greco FA, et al (2011). Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol, 29, 2582-9. DOI ScienceOn |
11 | Takezawa K, Okamoto I, Yonesaka K, et al (2009). Sorafenib inhibits non small cell lung cancer cell growth by targeting B RAF in KRAS wild type cells and C RAF in KRAS mutant cells. Cancer Res, 69, 6515-21. DOI ScienceOn |
12 | Wakelee HA, Lee JW, Hanna NH, et al (2012). A double- blind randomized discontinuation phase-ii study of sorafenib (BAY 43- 9006) in previously treated non-small-cell lung cancer patients: Eastern Cooperative Oncology Group Study E2501. J Thorac Oncol, 7, 1574-82. DOI |
13 | Wilhelm SM, Adnane L, Newell P, et al (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf, VEGF and PDGF receptor signaling. Mol Cancer Ther, 7, 3129-40. DOI ScienceOn |
14 | Wilhelm SM, Carter C, Tang L, et al. (2004). Bay 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 64, 7099-109. DOI ScienceOn |
15 | Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300 DOI |
16 | Hauschild A, Agarwala SS, Trefzer U, et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol, 27, 2823-30 DOI ScienceOn |
17 | Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BMJ, 327, 557-60 DOI ScienceOn |
18 | Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 17, 1-12 DOI ScienceOn |
19 | Kemmer K, Corless CL, Fletcher JA, et al (2004). Kit mutations are common in testicular seminomas. Am J Pathol, 164, 305-13 DOI ScienceOn |
20 | Kindler T, Lipka DB, Fischer T (2010). Flt3 as a therapeutic target in aml: still challenging after all these years. Blood, 116, 5089-102 DOI |
21 | Li J, Pan YY, Zhang Y (2013). Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. Oncol Lett, 5, 440-6. |
22 | Lind JS, Dingemans AM, Groen HJ, et al (2010). A multicenter phase II study of erlotinib and sorafenib in chemotherapynaive patients with advanced non-small cell lung cancer. Clin Cancer Res, 16, 3078-87. DOI |
23 | Llovet JM, Ricci S, Mazzaferro V, et al. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 359, 378-90 DOI ScienceOn |
24 | Maurer G, Tarkowski B, Baccarini M (2011) Raf kinases in cancer-roles andtherapeutic opportunities. Oncogene, 30, 3477-88 DOI |
25 | Paz-Ares LG, Biesma B, Heigener D, et al (2012). Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the firstline treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol, 30, 3084-92. DOI |
26 | Metro G, Minotti V, Crino L (2012). Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one? J Thorac Dis, 4, 635-8. |
27 | Molina JR, Dy GK, Foster NR, et al (2011). A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. J Clin Oncol, 29, (suppl; abstr 7513). |
28 | Paz-Ares L, Hirsh V, Zhang L, et al (2012). Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III, randomized, double-blind, placebocontrolled MISSION trial (abstract). Ann Oncol, 23, 33. DOI |
29 | Plastaras JP, Kim SH, Liu YY, et al (2007). Cell cycle dependent and schedule- dependent antitumor effects of sorafenib combined with radiation. Cancer Res, 67, 9443 54. |
30 | Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH (2006). Paclitaxel- carboplatin alone or with bevacizumab for nonsmall- cell lung cancer. N Engl J Med, 355, 2542-50 DOI ScienceOn |
31 | Scagliotti G, Novello S, von Pawel J, et al (2010). Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol, 28, 1835-42. DOI ScienceOn |
32 | Schiller JH, Harrington D, Belani CP, Langer C, Sandler A (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8 DOI ScienceOn |